Clinical value of Ticagrelor in the treatment of acute coronary syndrome

ZHANG Tao; ZHAO Xian-xian

doi:10.16048/j.issn.2095-5561.2019.01.03

Abstract：Objective To investigate the clinical value of Ticagrelor in the treatment of acute coronary syndrome (ACS). Methods A retrospective study was performed on 120 cases of patients with ACS who were admitted from January 2015 to January 2016.Patients were randomly divided into the Group A and Group B, with 60 cases in each group.Patients in the Group A were given Clopidogrel combined with asprin, the others in the Group B were given Ticagrelor combined with asprin.The effective rate, plasma viscosity, whole blood viscosity, platelet aggregation rate, adverse cardiovascular events and complications were compared between the two groups.Results The total effective rate of the Group B was 93.3％ (56/60), which was significantly higher than 81.7％ (49/60) of the Group A (P＜0.05). After treatment, plasma viscosity, whole blood viscosity and platelet aggregation rate of the two groups were significantly lower than those before treatment, and the above indexes of the patients in Group B were lower than those in Group A (P＜0.05). The incidence of adverse cardiovascular events in Group B was 11.7％ (7/60), significantly lower than 31.7％ (19/60) in Group A (P＜0.05). No severe bleeding occurred in either group.In Group A, there were 4 cases of bleeding and 1 case of dyspnea, and the complication rate was 8.3％ (5/60). Six patients in Group B had bleeding and one had dyspnea, and the incidence of complications was11.7％ (7/60). There was no significant difference in the incidence of complications between the two groups (P＞0.05). Conclusion Ticagrelor is effective in the treatment of acute coronary syndrome, which can effectively reduce the incidence of adverse cardiovascular events with high safety.